CONCORDBIO Q1 FY27 results at a glance
CONCORD BIOTECH LIMITED Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹257 cr |
|---|
| Revenue YoY | +26.2% |
|---|
| Operating profit | ₹64.28 cr |
|---|
| Operating margin | 25.0% |
|---|
| Net profit | ₹57.7 cr |
|---|
| Net profit YoY | +31.0% |
|---|
| Net profit QoQ | -35.0% |
|---|
| Net margin | 22.4% |
|---|
| Basic EPS | ₹8.46 |
|---|
| TTM revenue | ₹1,108 cr |
|---|
| TTM net profit | ₹273 cr |
|---|
| TTM net margin | 24.6% |
|---|
CONCORDBIO Q1 FY27 results: what the numbers say
CONCORD BIOTECH LIMITED (CONCORDBIO) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹257 cr and a net profit of ₹57.7 cr, translating into earnings per share of ₹8.46.
Compared with the same quarter a year earlier, revenue grew strongly by +26.2% and net profit grew strongly by +31.0%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹64.28 cr, an operating margin of 25.0% versus 21.4% a year ago — a gain of 3.6 percentage points.
CONCORDBIO quarter-wise results table
Net profit
₹57.7 cr
+31.0% YoY
Operating profit
₹64.28 cr
+47.4% YoY
CONCORD BIOTECH LIMITED (CONCORDBIO) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹257 cr | ₹64.28 cr | ₹57.7 cr | 25.0% | 22.4% | ₹8.46 | +31.0% | -35.0% |
| Q4 FY262026-03-31 | ₹326 cr | ₹98.99 cr | ₹88.79 cr | 30.4% | 27.2% | ₹8.46 | — | +39.5% |
| Q3 FY262025-12-31 | ₹278 cr | ₹80.23 cr | ₹63.64 cr | 28.9% | 22.9% | ₹6.08 | — | +0.9% |
| Q2 FY262025-09-30 | ₹247 cr | ₹70.1 cr | ₹63.06 cr | 28.4% | 25.5% | ₹6.03 | — | +43.1% |
| Q1 FY262025-06-30 | ₹204 cr | ₹43.62 cr | ₹44.06 cr | 21.4% | 21.6% | ₹4.21 | — | — |
| TTM (last 4 quarters) | ₹1,108 cr | ₹314 cr | ₹273 cr | 28.3% | 24.6% | ₹29.03 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
CONCORDBIO quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
CONCORD BIOTECH LIMITED quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹257 cr | ₹326 cr | ₹278 cr | ₹247 cr | ₹204 cr |
|---|
| Total expenses | ₹193 cr | ₹227 cr | ₹198 cr | ₹177 cr | ₹160 cr |
|---|
| Gross profit | ₹203 cr | ₹240 cr | ₹212 cr | ₹198 cr | ₹159 cr |
|---|
| Operating profit (EBIT) | ₹64.28 cr | ₹98.99 cr | ₹80.23 cr | ₹70.1 cr | ₹43.62 cr |
|---|
| Operating margin | 25.0% | 30.4% | 28.9% | 28.4% | 21.4% |
|---|
| Interest cost | ₹0.04 cr | ₹0.08 cr | ₹0.08 cr | ₹0.06 cr | ₹0.06 cr |
|---|
| Profit before tax | ₹78.34 cr | ₹114 cr | ₹86.16 cr | ₹85.68 cr | ₹58.73 cr |
|---|
| Tax expense | ₹20.65 cr | ₹25.61 cr | ₹22.51 cr | ₹22.62 cr | ₹14.67 cr |
|---|
| Effective tax rate | 26.4% | 22.4% | 26.1% | 26.4% | 25.0% |
|---|
| Net profit (PAT) | ₹57.7 cr | ₹88.79 cr | ₹63.64 cr | ₹63.06 cr | ₹44.06 cr |
|---|
| Net profit margin | 22.4% | 27.2% | 22.9% | 25.5% | 21.6% |
|---|
| Basic EPS | ₹8.46 | ₹8.46 | ₹6.08 | ₹6.03 | ₹4.21 |
|---|
| Diluted EPS | ₹8.46 | ₹8.46 | ₹6.08 | ₹6.03 | ₹4.21 |
|---|
CONCORDBIO results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +26.2% | — | — | — | — |
|---|
| Revenue QoQ | -21.0% | +17.4% | +12.4% | +21.1% | — |
|---|
| Operating profit YoY | +47.4% | — | — | — | — |
|---|
| Operating profit QoQ | -35.1% | +23.4% | +14.5% | +60.7% | — |
|---|
| Net profit YoY | +31.0% | — | — | — | — |
|---|
| Net profit QoQ | -35.0% | +39.5% | +0.9% | +43.1% | — |
|---|
| EPS YoY | +101.0% | — | — | — | — |
|---|
| EPS QoQ | 0.0% | +39.1% | +0.8% | +43.2% | — |
|---|
CONCORDBIO annual results history
Full-year performance for CONCORD BIOTECH LIMITED, useful for reading each quarter in context.
CONCORD BIOTECH LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹1,046 cr | ₹1,180 cr | ₹998 cr | ₹831 cr |
|---|
| Total expenses | ₹742 cr | ₹716 cr | ₹612 cr | ₹526 cr |
|---|
| Gross profit | ₹786 cr | ₹862 cr | ₹756 cr | ₹634 cr |
|---|
| Operating profit (EBIT) | ₹305 cr | ₹463 cr | ₹386 cr | ₹305 cr |
|---|
| Operating margin | 29.1% | 39.3% | 38.7% | 36.7% |
|---|
| Interest cost | ₹0.28 cr | ₹0.53 cr | ₹2.55 cr | ₹4.51 cr |
|---|
| Profit before tax | ₹345 cr | ₹495 cr | ₹413 cr | ₹322 cr |
|---|
| Tax expense | ₹85.42 cr | ₹123 cr | ₹104 cr | ₹81.93 cr |
|---|
| Effective tax rate | 24.8% | 24.9% | 25.3% | 25.4% |
|---|
| Net profit (PAT) | ₹261 cr | ₹372 cr | ₹308 cr | ₹240 cr |
|---|
| Net profit margin | 24.9% | 31.5% | 30.9% | 28.9% |
|---|
| Basic EPS | ₹24.78 | ₹35.52 | ₹29.45 | ₹22.95 |
|---|
| Diluted EPS | ₹24.78 | ₹35.52 | ₹29.45 | ₹22.95 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹257 cr against ₹204 cr in Q1 FY26, and ₹326 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -21.0%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹193 cr, or 75.0% of revenue, with operating profit grew +47.4% year on year.
Margins, tax and profitability
Net profit of ₹57.7 cr works out to a net margin of 22.4% compared with 21.6% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, CONCORD BIOTECH LIMITED reported profit before tax of ₹78.34 cr, a tax charge of ₹20.65 cr (effective rate 26.4%), interest cost of ₹0.04 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹88.79 cr in Q4 FY26 to ₹57.7 cr in Q1 FY27, a change of -35.0%.
Trailing twelve months and annual context
Across the trailing four quarters CONCORD BIOTECH LIMITED has generated revenue of ₹1,108 cr and net profit of ₹273 cr, a trailing net margin of 24.6%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹1,046 cr with net profit of ₹261 cr and EPS of ₹24.78, versus the prior year where revenue declined -11.3% and profit declined -29.8%.
What to watch in the next CONCORDBIO quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
CONCORD BIOTECH LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
CONCORDBIO results coverage
No results report published for CONCORDBIO yet — our desk covers each quarter within minutes of the filing.
CONCORDBIO quarterly results FAQs
What were CONCORD BIOTECH LIMITED (CONCORDBIO) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), CONCORD BIOTECH LIMITED reported revenue of ₹257 cr and net profit of ₹57.7 cr, a change of +31.0% year on year on +26.2% revenue growth. EPS stood at ₹8.46.
What is CONCORDBIO profit margin in Q1 FY27?
CONCORD BIOTECH LIMITED posted a net profit margin of 22.4% and an operating margin of 25.0% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹1,108 cr and net profit ₹273 cr.
Did CONCORDBIO results beat the previous quarter?
CONCORD BIOTECH LIMITED net profit changed -35.0% quarter on quarter, from ₹88.79 cr in Q4 FY26 to ₹57.7 cr in Q1 FY27.
When are CONCORD BIOTECH LIMITED (CONCORDBIO) quarterly results?
CONCORD BIOTECH LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see CONCORDBIO latest quarterly results?
Results coverage for CONCORDBIO will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the CONCORDBIO stock page.
What is CONCORD BIOTECH LIMITED annual revenue and profit?
For FY26, CONCORD BIOTECH LIMITED reported full-year revenue of ₹1,046 cr and net profit of ₹261 cr, with EPS of ₹24.78.
How many quarterly results has CONCORDBIO declared recently?
Past results dates for CONCORDBIO will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
